These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 12654440

  • 1. Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas.
    Chen C, Shu HK, Goldwein JW, Womer RB, Maity A.
    Int J Radiat Oncol Biol Phys; 2003 Apr 01; 55(5):1294-9. PubMed ID: 12654440
    [Abstract] [Full Text] [Related]

  • 2. Parameningeal rhabdomyosarcoma: outcomes and opportunities.
    Yang JC, Wexler LH, Meyers PA, Wolden SL.
    Int J Radiat Oncol Biol Phys; 2013 Jan 01; 85(1):e61-6. PubMed ID: 23021437
    [Abstract] [Full Text] [Related]

  • 3. Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide.
    Casey DL, Wexler LH, Wolden SL.
    Int J Radiat Oncol Biol Phys; 2019 Apr 01; 103(5):1151-1157. PubMed ID: 30508617
    [Abstract] [Full Text] [Related]

  • 4. The challenging role of radiation therapy for very young children with rhabdomyosarcoma.
    Puri DR, Wexler LH, Meyers PA, La Quaglia MP, Healey JH, Wolden SL.
    Int J Radiat Oncol Biol Phys; 2006 Jul 15; 65(4):1177-84. PubMed ID: 16682130
    [Abstract] [Full Text] [Related]

  • 5. Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood.
    Douglas JG, Arndt CA, Hawkins DS.
    Eur J Cancer; 2007 Apr 15; 43(6):1045-50. PubMed ID: 17368885
    [Abstract] [Full Text] [Related]

  • 6. Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma.
    Buszek SM, Ludmir EB, Grosshans DR, McAleer MF, McGovern SL, Harrison DJ, Okcu MF, Chintagumpala MM, Mahajan A, Paulino AC.
    Int J Radiat Oncol Biol Phys; 2021 Mar 01; 109(3):718-725. PubMed ID: 33516439
    [Abstract] [Full Text] [Related]

  • 7. Intensity-modulated radiotherapy with use of cone-down boost for pediatric head-and-neck rhabdomyosarcoma.
    McDonald MW, Esiashvili N, George BA, Katzenstein HM, Olson TA, Rapkin LB, Marcus RB.
    Int J Radiat Oncol Biol Phys; 2008 Nov 01; 72(3):884-91. PubMed ID: 18455321
    [Abstract] [Full Text] [Related]

  • 8. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.
    Baker KS, Anderson JR, Link MP, Grier HE, Qualman SJ, Maurer HM, Breneman JC, Wiener ES, Crist WM.
    J Clin Oncol; 2000 Jun 01; 18(12):2427-34. PubMed ID: 10856103
    [Abstract] [Full Text] [Related]

  • 9. [Rhabdomyosarcoma in middle to old-aged patients: analysis of clinicopathological features and prognosis in 76 cases].
    Yu L, Wang J.
    Zhonghua Zhong Liu Za Zhi; 2012 Dec 01; 34(12):910-6. PubMed ID: 23336377
    [Abstract] [Full Text] [Related]

  • 10. Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma.
    Buszek SM, Ludmir EB, Grosshans DR, McAleer MF, McGovern SL, Harrison DJ, Okcu MF, Chintagumpala MM, Mahajan A, Paulino AC.
    Pediatr Blood Cancer; 2019 Nov 01; 66(11):e27952. PubMed ID: 31397065
    [Abstract] [Full Text] [Related]

  • 11. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
    Wolden SL, Lyden ER, Arndt CA, Hawkins DS, Anderson JR, Rodeberg DA, Morris CD, Donaldson SS.
    Int J Radiat Oncol Biol Phys; 2015 Dec 01; 93(5):1071-6. PubMed ID: 26581144
    [Abstract] [Full Text] [Related]

  • 12. [Orbital rhabdomyosarcoma: difficulties with European treatment protocol].
    Olivier Pascual N, Calvo JM, Abelairas Gómez JM.
    Arch Soc Esp Oftalmol; 2005 Jun 01; 80(6):331-8. PubMed ID: 15986273
    [Abstract] [Full Text] [Related]

  • 13. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects.
    Childs SK, Kozak KR, Friedmann AM, Yeap BY, Adams J, MacDonald SM, Liebsch NJ, Tarbell NJ, Yock TI.
    Int J Radiat Oncol Biol Phys; 2012 Feb 01; 82(2):635-42. PubMed ID: 21377294
    [Abstract] [Full Text] [Related]

  • 14. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR.
    J Clin Oncol; 2011 Apr 01; 29(10):1312-8. PubMed ID: 21357783
    [Abstract] [Full Text] [Related]

  • 15. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan A, Parham DM, Cripe TP, Anderson JR, Meyer WH, Hawkins DS.
    Cancer; 2017 Jun 15; 123(12):2368-2375. PubMed ID: 28211936
    [Abstract] [Full Text] [Related]

  • 16. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84.
    Flamant F, Rodary C, Rey A, Praquin MT, Sommelet D, Quintana E, Theobald S, Brunat-Mentigny M, Otten J, Voûte PA, Habrand JL, Martelli H, Barrett A, Terrier-Lacombe MJ, Oberlin O.
    Eur J Cancer; 1998 Jun 15; 34(7):1050-62. PubMed ID: 9849454
    [Abstract] [Full Text] [Related]

  • 17. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.
    Breneman J, Meza J, Donaldson SS, Raney RB, Wolden S, Michalski J, Laurie F, Rodeberg DA, Meyer W, Walterhouse D, Hawkins DS.
    Int J Radiat Oncol Biol Phys; 2012 Jun 01; 83(2):720-6. PubMed ID: 22104356
    [Abstract] [Full Text] [Related]

  • 18. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Breitfeld PP, Lyden E, Raney RB, Teot LA, Wharam M, Lobe T, Crist WM, Maurer HM, Donaldson SS, Ruymann FB.
    J Pediatr Hematol Oncol; 2001 May 01; 23(4):225-33. PubMed ID: 11846301
    [Abstract] [Full Text] [Related]

  • 19. Brachytherapy as part of the multidisciplinary treatment of childhood rhabdomyosarcomas of the orbit.
    Blank LE, Koedooder K, van der Grient HN, Wolffs NA, van de Kar M, Merks JH, Pieters BR, Saeed P, Baldeschi L, Freling NJ, Koning CC.
    Int J Radiat Oncol Biol Phys; 2010 Aug 01; 77(5):1463-9. PubMed ID: 19864080
    [Abstract] [Full Text] [Related]

  • 20. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
    Xu N, Duan C, Jin M, Zhang DW, Su Y, Yu T, He LJ, Fu LB, Zeng Q, Wang HM, Zhang WP, Ni X, Ma XL.
    Zhonghua Er Ke Za Zhi; 2019 Oct 02; 57(10):767-773. PubMed ID: 31594063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.